FILTER
FILTERED INTERVIEW RESULTS
Sergio Hernández Núñez
EXECUTIVE VICE PRESIDENT, CHILEAN COPPER COMMISSION (COCHILCO)
Cochilco provides the Chilean copper mining industry with vital strategic information with which to guide strategy.
Nigel Forrester
MANAGING DIRECTOR, MOUNT BURGESS
Mount Burgess’ Kihabe project in Botswana is preparing a feasibility study this year as it aims at significant zinc production.
Pedro Damjanic
SENIOR VP OF MINING, FINNING CHILE
Finning Chile explains how its Caterpillar equipment business adapted to current conditions and how it envisages the next.
James Hume
PRESIDENT, EAGLE MAPPING
Eagle Mapping are busy Lidar scanning the northern parts of B.C. and Yukon from the air.
Stephen Keith
PRESIDENT, GROWMAX RESOURCES
Recently re-branded GrowMax Resources explains how it intend to develop its fertilizer assets in Peru.
Dale Clayton
MANAGING DIRECTOR, LIEBHERR
Lieberr sees Chile as a good opportunity to diversify its commodity exposure and is building a firm presence there.
Ivan Rayo
GENERAL MANAGER, JRI INGENIERÍA
Chilean engineering company JRI describes how experience and innovation have helped the company to expand.
Martin Staples
DIRECTOR, AMC CONSULTANTS
AMC Consultants describe how the company managed the downturn and some of its implications for Western Australian mining.
Robert Archer
PRESIDENT & CEO, GREAT PANTHER SILVER
Great Panther Silver made a foray into Peru last year with the acquisition of the Coricancha mine complex which it intends to bring to production swiftly.
Walter Coles
PRESIDENT & CEO, SKEENA RESOURCES LIMITED
Skeena Resources has built up an interesting portfolio of mines based around the Golden Triangle.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
